Rejuvenate Bio Secures $6 Million Funding and Teams Up with Merck Animal Health to Innovate Gene Therapy

Rejuvenate Bio Secures $6 Million Financing and R&D Collaboration with Merck Animal Health

In a significant leap forward for veterinary healthcare, Rejuvenate Bio, a promising biotechnology company, has successfully closed a financing round of $6 million. This funding was spearheaded by VCapital, with key participation from renowned partners such as Merck Animal Health, Connecticut Innovations, and Digitalis. The funds are earmarked to bolster the company’s advancements in gene therapy, a groundbreaking approach aimed at treating chronic and age-associated diseases in companion animals.

Strategic Collaboration with Merck Animal Health

Alongside the financing achievement, Rejuvenate Bio has entered a pivotal strategic research and development collaboration with Merck Animal Health. This partnership aims to propel a novel gene therapy program tailored for animal health. By harnessing Rejuvenate Bio's proprietary platform technologies and its expertise in translational science, both entities will work towards improving the health and lifespan of pets that suffer from chronic ailments.

Andrew Worden, a founding partner at Lifespan Vision Ventures, expressed their pride in Rejuvenate Bio's accomplishments, stating, "We are proud to see Rejuvenate Bio reach this important milestone. The confidence shown by Merck Animal Health—both as an investor and a collaborator—speaks to the strength of the team and the promise of their science. Lifespan Vision Ventures is delighted to continue supporting their mission to address some of the most significant unmet needs in companion animal and human health."

Expanding the Gene Therapy Pipeline

Rejuvenate Bio is trailblazing in the biotechnology sector by developing innovative gene therapies aimed at extending healthy lifespans. Their focused approach addresses the modification of biological pathways that are associated with aging, utilizing targeted genetic interventions. The company’s goal is to create therapies that not only increase longevity but also enhance the quality of life for both animals and humans alike.

Headquartered in sunny San Diego, California, Rejuvenate Bio's initiatives are based on rigorous scientific research that originated at the Wyss Institute at Harvard Medical School. The firm has made remarkable strides in developing therapies designed to combat chronic age-related diseases, showcasing its potential impact on veterinary medicine.

Lifespan Vision Ventures: A Catalyst for Future Innovations

Lifespan Vision Ventures is not just a financial backer; it is a global venture capital firm dedicated to investing in early-stage biotech companies that are pushing the envelope with breakthrough technologies. Its focus lies in preventing and treating age-related diseases while fostering healthy aging. By partnering with visionary founders and supporting science-driven solutions, Lifespan aims to create a future where longevity is accompanied by enhanced quality of life.

As the collaboration with Merck Animal Health evolves, stakeholders in the animal healthcare sector will keenly watch for advancements that could redefine how chronic and age-related diseases are treated in pets. With Rejuvenate Bio at the forefront of this innovation, the future looks promising for developing effective therapies that improve the healthspan of our beloved companion animals.

For additional information or to keep abreast of their latest developments, visit Rejuvenate Bio's website.